Literature DB >> 1733533

Carboxypeptidase N concentration during cardiopulmonary bypass in humans.

S F Rabito1, R Anders, W Soden, R A Skidgel.   

Abstract

Carboxypeptidase N (CPN) is an inactivator of anaphylatoxins and kinins, peptides implicated in the pathogenesis of complications in extracorporeal circulation. To investigate whether the level of CPN is altered during cardiopulmonary bypass (CPB) we studied 15 patients undergoing cardiac surgery utilizing CPB. The concentration of CPN decreased to about 48% of the initial value upon initiation of CPB and remained low throughout the procedure. A similar decrease was observed in the level of alkaline phosphatase, an enzyme that was measured to assess the degree of haemodilution. When the data were normalized for dilution, no difference in the concentration of CPN was observed during CPB. Moreover, no changes in the concentration of CPN were observed when protamine was given to neutralize heparin and none of the 15 patients experienced any side-effects of protamine administration. We conclude that the decrease in CPN during CPB was due primarily to dilution and not to changes in CPN synthesis or catabolism. Protamine administration is not associated with significant changes in the level of CPN in patients who have an asymptomatic reversal of heparin anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733533     DOI: 10.1007/BF03008673

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  30 in total

1.  Probable reversal of protamine reactions by heparin administration.

Authors:  R Lock; E A Hessel
Journal:  J Cardiothorac Anesth       Date:  1990-10

2.  Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins.

Authors:  F Tan; H Jackman; R A Skidgel; E K Zsigmond; E G Erdös
Journal:  Anesthesiology       Date:  1989-02       Impact factor: 7.892

3.  Pulmonary injury secondary to extracorporeal circulation. An ultrastructural study.

Authors:  N B Ratliff; W G Young; D B Hackel; E Mikat; J W Wilson
Journal:  J Thorac Cardiovasc Surg       Date:  1973-03       Impact factor: 5.209

4.  The hemostatic response to open-heart operations.

Authors:  H R Gralnick; R D Fischer
Journal:  J Thorac Cardiovasc Surg       Date:  1971-06       Impact factor: 5.209

5.  Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin.

Authors:  E Lowenstein; W E Johnston; D G Lappas; M N D'Ambra; R C Schneider; W M Daggett; C W Akins; D M Philbin
Journal:  Anesthesiology       Date:  1983-11       Impact factor: 7.892

6.  Complement and the damaging effects of cardiopulmonary bypass.

Authors:  S Westaby
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

7.  Changes in serum angiotensin-converting enzyme during cardiopulmonary bypass in humans.

Authors:  A B Gorin; J Liebler
Journal:  Am Rev Respir Dis       Date:  1986-07

8.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.

Authors:  D E Chenoweth; S W Cooper; T E Hugli; R W Stewart; E H Blackstone; J W Kirklin
Journal:  N Engl J Med       Date:  1981-02-26       Impact factor: 91.245

9.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency.

Authors:  K P Mathews; J G Curd; T E Hugli
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

View more
  1 in total

Review 1.  Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Int Immunopharmacol       Date:  2007-08-15       Impact factor: 4.932

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.